DRUGS ON THE MOVE
1. In Breast cancer
-Everolimus
-Pertuzumab
-T-DM-1
2. In Prostate cancer
-Abiraterone (Zytiga)
-Enzalutmide (Xtandi)
-Alpharadin (Radium 223)
3. Other
-Cabozantinib
-Orteronel
-Curtisen
-Tasquinimod
4. Melanoma
-Dabrafenib
-Trametinib
-GDC- 0973
-Vemurafenib (Zelboraf)
-Nivolumab
-Ipilimumab
-MK3754
5. Lung cancers
-Crizotinib
-Afatinib
-Dacomitinib
-Nivolumab
- Selumetinib
5. Thyroid cancer
-Pazopanib
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Showing posts with label enzalutmide. Show all posts
Showing posts with label enzalutmide. Show all posts
Wednesday, February 27, 2013
DRUGS ON THE MOVE
Labels:
abiraterone,
alpharadin,
breast cancer,
cabozantinib,
crbcm,
curtisen,
enzalutmide,
everolimus,
lung cancers,
melanoma,
orteronel,
pertuzumab,
prostate cancer,
T-DM-1,
tasquinimod,
thyroid cancer
Subscribe to:
Posts (Atom)